Washington, July 4 (V7N) – U.S.-based private equity giant Carlyle Group is preparing to offload up to a 10% stake in Piramal Pharma, one of India’s leading pharmaceutical companies, in a deal expected to raise between ₹26 billion and ₹27 billion (approximately $304.8 million), according to sources cited by online news portal Moneycontrol on Thursday.

The sale is planned through block trades, a mechanism that allows large institutional investors to buy or sell substantial volumes of shares directly, thereby minimizing market price fluctuations during the transaction. This method is widely preferred for large-scale stake sales to maintain market stability.

Carlyle Group acquired its significant holding in Piramal Pharma following the company’s demerger from the Piramal Group in 2020. Since then, the private equity firm has been a major investor in the company, which is listed on the National Stock Exchange (NSE) under the ticker PIRM.NS.

Piramal Pharma has been in the spotlight recently for its strong performance, driven largely by its expanding contract development and manufacturing organization (CDMO) business and critical care divisions. These segments have attracted increased investor interest, reflecting confidence in the company’s long-term growth potential and robust fundamentals.

The proposed divestment aligns with a growing trend of private equity firms exiting investments in the Indian pharmaceutical sector, which has witnessed a surge in foreign direct investment and private equity inflows in the last decade. This sector has become a key area of focus globally due to rising demand for pharmaceutical products and contract manufacturing services.

Industry analysts view Carlyle’s planned stake sale as a strategic move to capitalize on favorable market conditions and maximize returns from its investment in one of India’s fastest-growing pharmaceutical companies. The transaction, if executed successfully, will mark a significant liquidity event in the sector.

At the time of reporting, neither Carlyle Group nor Piramal Pharma has issued an official statement regarding the impending transaction.

END/WD/SMA/